ArticleFuture oncology (London, England)2025

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.